Long-Term Debt Volume: Syros Pharmaceuticals, Inc (SYRS)

Graphic logo of Syros (SYRS)

Syros Pharmaceuticals (SYRS) develops innovative oncology treatments through the management of gene expression. This chart's price trend confirms the business's financial sensitivity to borrowing costs amid stable demand for its research. The current indicator is 0.00. The company's high standing among experts stems from its unique approach to restructuring cellular mechanisms. Meanwhile, technology patents currently require updates due to the complexity of passing FDA regulatory reviews.

syros.com (SYRS) Company Long-Term Debt: for the period 07/04/2022 - 03/29/2025

Summary analytical data breakdowns for Syros (SYRS)

- market price and analyst price targets:
Stock Price syros.com|SYRS - Price Target Chart
- company stock exchange capitalization indicators:
Market Capitalization Syros Pharmaceuticals|SYRS - Real Price to Acquire Entire Company
- balance sheet equity data:
Net Asset Value per Share Syros Pharmaceuticals|SYRS - Company Book Value|Market Value to Book Value syros.com|SYRS - Aggregate Company Assets
- company total debt and liquidity indicators:
Debt to Capital Syros Pharmaceuticals|SYRS - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient Syros Pharmaceuticals, Inc|SYRS - Company Total Debt|Debt to Net Assets Ratio Syros Pharmaceuticals|SYRS - Company Long-Term Debt|Current Liabilities Syros Pharmaceuticals|Intermediate Coverage Ratio syros.com
- earnings and market multiples details:
SYRS - Net Profit
Fundamental company valuation:syros.com
Manufactured product of Syros Pharmaceuticals

Long-term debt aggregates all obligations with maturities exceeding twelve months, determining the issuer's financial stability and credit risk. For Syros Pharmaceuticals (SYRS), the status of the corporation's long-term loans and borrowings reflects the cost of scaling its gene regulation platform. Investors must weigh this volume against the potential for future licensing payments from pharma behemoths. An increase in borrowings is acceptable only if the development of targeted therapy accelerates. Excessive debt leverage could limit the operational flexibility of the biotechnology business.

Competitors of Syros Pharmaceuticals (SYRS)

Company Long-Term Debts Tempus Labs TEM|QGEN - Company Long-Term Debt|Long-Term Debt Volume Ionis Pharmaceuticals, Inc. IONS|RGEN (Repligen Corp.) - Company Long-Term Liabilities|Long-Term Debt Avidity Corp (RNA)|Company Long-Term Debt CRISPR Therapeutics AG|WGS: Company Long-Term Loans and Borrowings|Company Long-Term Debt Ultragenyx (RARE)|BEAM - Long-Term Debt|Company Long-Term Debt Sarepta Therapeutics Inc SRPT|Long-Term Debt Volume Twist Bioscience Corp (TWST)|TXG: Company Long-Term Liabilities|Company Long-Term Loans and Borrowings NTLA (intelliatx.com)|Stoke Therapeutics, Inc. (STOK) - Company Long-Term Debt|Long-Term Liabilities BLFS (BioLife Solutions Inc)|WVE (Wave Life Sciences Corp) - Company Long-Term Debts|MAZE: Company Long-Term Loans and Borrowings|Company Long-Term Debts SION|Company Long-Term Debts primemedicine.com (PRME)|Company Long-Term Debt Taysha Gene Therapies, Inc. TSHA|Company Long-Term Loans and Borrowings QURE|MGTX - Company Long-Term Debt|REGENXBIO Corp (RGNX) - Company Long-Term Liabilities|SLDB: Company Long-Term Debts|ocugen.com (OCGN) - Company Long-Term Debts|PACB (PacBio) - Company Long-Term Debts|Company Long-Term Liabilities Benitec Biopharma Inc (BNTC)|Company Long-Term Debts DSGN|RCKT - Long-Term Debt|4D Molecular Therapeutics - Company Long-Term Liabilities|Company Long-Term Debts Lexeo Therapeutics Inc. LXEO|KRRO: Company Long-Term Liabilities|Editas Medicine Inc - Amount of Long-Term Liabilities|SLN: Company Long-Term Debts|PRQR - Long-Term Debt Volume|CDXS (Codexis Inc) - Company Long-Term Debts|Company Long-Term Liabilities sangamo.com (SGMO)|Company Long-Term Debts NAUT|Company Long-Term Debts Metagenomi Inc. (MGX)|Company Long-Term Debt Precision BioSciences DTIL|Generation Bio Co - Company Long-Term Debt|BOLD - Company Long-Term Debt|Long-Term Debt Volume Exicure, Inc. XCUR|imunon.com (IMNN) - Company Long-Term Debt|PHIO - Long-Term Debt Volume|Company Long-Term Liabilities MBIO|Long-Term Debt TransCode RNAZ|Company Long-Term Debt Bionano Genomics, Inc. (BNGO)|APDN (adnas.com) - Company Long-Term Loans and Borrowings|Company Long-Term Debt bluebird bio BLUE|Long-Term Debt Volume ImmunoPrecise Antibodies Ltd (IPA)|Omega - Company Long-Term Debts|OMIC (Singular Genomics Corp) - Company Long-Term Indebtedness|Regulus Therapeutics (RGLS) - Company Long-Term Debt|Company Long-Term Indebtedness TBIO|TCON (TRACON Pharmaceuticals, Inc.) - Company Long-Term Debts|Company Long-Term Debts Unity Biotechnology Inc.